Note to our followers: Our nearly 13-year run of daily publication of new content on came to a close at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. But all of the 6,000+ articles we have published contain lessons to help you improve your critical thinking about health care interventions. And those will be still be alive on the site for a couple of years.

Tags: immunotherapy


Reuters story on kidney cancer drug makes us ask: How is this journalism?


Immunotherapy prolongs survival, but at what cost? Washington Post needed more on treatment downsides


Without any independent sources providing insight, readers of TIME’s coverage on lung cancer immunotherapy mostly left in the dark


Washington Post wisely quantifies severe side effects and deaths from CAR-T cell therapy


AP’s story on cancer immunotherapy quickly mentions low success rate


Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000


It’s misleading to call results from phase 1 trials with 6 and 13 patients a ‘cancer breakthrough’


Immunotherapy’s ‘new era:’ LA Times story overlooks the risks and overstates trial results


Keytruda for bladder cancer: No independent scrutiny of Merck-reported results


‘Promising’ new lymphoma treatment gets superficial, one-sided coverage by CBS